缬沙坦/氢氯噻嗪治疗原发性高血压有效性和安全性的Meta分析

Meta-analysis of efficacy and safety of valsartan/hydrochlorothiazide in the treatment of essential hypertension

目的评价复方缬沙坦(缬沙坦/氢氯噻嗪)治疗原发性高血压的有效性及安全性。方法计算机检索中国期刊全文数据库和中国生物医学文献数据库,使用RevMan4.2软件进行评价。结果共纳入12篇随机对照试验,Meta分析结果显示:复方缬沙坦与缬沙坦相比,有效率的差异有统计学意义[OR=2.94,95%CI(2.00,4.32),P<0.01],而不良反应发生率的差异无统计学意义[OR=0.91,95%CI(0.55,1.49),P=0.70];与其它含氢氯噻嗪的复方制剂相比,有效率和不良反应发生率的差异均无统计学意义。结论复方缬沙坦治作为一种新型的固定剂量降压制剂,降压效果优良。

Aim To evaluate the efficacy and safety of compound valsartan in treating essential hypertension. Methods CNKI and CBM were retrieved. Data analyses were performed with the Cochrane Collaboration＇ s RevMan 4.2 software. Results Twelve RCTs were in- cluded. Meta-analyses showed that the effective rate in patients receiving compound valsartan was significantly higher than those receiving valsartan, while there was no significant difference in the rate of adverse events. No significant differences in the effective rate and the rate of adverse events were observed between the compound valsartan and other hydrochlorothiazide compound formulations. Conclusion As a new fixed dose combination, compound valsartan is effective and safe in treating essential hypertension.